Menu
Search
|

Menu

Close
X

PRA Health Sciences Inc PRAH.OQ (NASDAQ Stock Exchange Global Select Market)

114.13 USD
+2.14 (+1.91%)
As of 3:59 PM EST
chart
Previous Close 111.99
Open 112.45
Volume 103,989
3m Avg Volume 173,481
Today’s High 114.25
Today’s Low 112.18
52 Week High 121.98
52 Week Low 79.49
Shares Outstanding (mil) 64.98
Market Capitalization (mil) 7,276.57
Forward P/E 89.26
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.92 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
2,142
FY17
2,259
FY16
1,812
EPS (USD)
FY18
1.300
FY17
1.522
FY16
1.038
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
89.26
35.95
Price to Sales (TTM)
vs sector
2.60
9.98
Price to Book (MRQ)
vs sector
7.47
4.53
Price to Cash Flow (TTM)
vs sector
37.13
26.23
Total Debt to Equity (MRQ)
vs sector
122.35
16.61
LT Debt to Equity (MRQ)
vs sector
122.35
13.07
Return on Investment (TTM)
vs sector
3.53
12.64
Return on Equity (TTM)
vs sector
8.73
13.82

EXECUTIVE LEADERSHIP

Colin Shannon
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $892,500.00
Bonus: $546,000.00
Michael Bonello
Chief Financial Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
Jeffrey Barber
Independent Director, Since 2014
Salary: --
Bonus: --
Alexander Dickinson
Independent Director, Since 2017
Salary: --
Bonus: --
Linda Grais
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4130 Parklake Ave Ste 400
RALEIGH   NC   27612-4462

Phone: +1919.7868200

PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.

SPONSORED STORIES